MET and lung cancer: Subsequent studies identified similar alterations in sporadic renal carcinoma, non-small-cell lung cancer (NSCLC), breast cancer, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma and other solid tumors [3–8]. The authors' group was the first to establish the oncogenic role of MET alterations in lung cancer through the identification of mutations in the MET juxtamembrane domain in NSCLC and in the Sema domain in small cell lung cancer [9–12].